Silvia Escribano Serrat Explores A Potential Role of EASIX as a Predictor of Refractoriness and Mortality in iTTP
Silvia Escribano Serrat, Research Fellow at Memorial Sloan Kettering Cancer Center, shared on LinkedIn:
”I am pleased to share this multicenter article on the potential role of EASIX as a predictor of refractoriness and mortality in iTTP.”
Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a severe thrombotic microangiopathy caused by profound ADAMTS13 deficiency; although caplacizumab speeds platelet recovery, about 15% of patients remain refractory and may experience persistent endothelial or microvascular injury.
This study assessed whether the Endothelial Activation and Stress Index (EASIX) can track endothelial dysfunction and predict refractoriness or mortality in iTTP.
Read the full article here.
Article: EASIX, a new tool to predict response and refractoriness in immune-mediated thrombotic thrombocytopenic purpura
Authors: Silvia Escribano Serrat, María Queralt Salas, Cristina Pascual-Izquierdo, Manuel Fernández Villalobos, Inés Gómez-Seguí, Teresa Fidalgo, Marta Fernández Docampo, Jorge Martínez Nieto, Óscar Lamas, Miquel Lozano, Joan Cid, Paola Charry, Marc Pino, Patricia Molina, Blanca De Moner, Álex Ramos, Ana Belén Moreno-Castaño, Julia Martínez-Sánchez, Ginés Escolar, Maribel Díaz-Ricart
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 9, 2026, 09:25Emma Groarke Shares A Comprehensive Review on VEXAS Syndrome
-
Jan 9, 2026, 09:13Anirban Sen Gupta Presents PlateChek
-
Jan 9, 2026, 08:58Oscar Pena Shares KDIGO 2026 Update: 5 Critical Changes for Anemia in CKD Management
-
Jan 9, 2026, 07:38Bartosz Hudzik on Subacute Coronary Occlusions: Navigating the Gray Zone in CAD Care
-
Jan 9, 2026, 07:27Gregory Piazza on The Role of D-Dimer in VTE Evaluation
-
Jan 9, 2026, 07:19Emmanuel J Favaloro Shares the 1st Article in a VWD Series Marking the 100-Year Anniversary
-
Jan 9, 2026, 07:07Taylor Robichaux on Recombinant ADAMTS13 Therapy in cTTP
-
Jan 9, 2026, 06:25Sara Ng: VTE Continues to Plague Modern Oncology
-
Jan 9, 2026, 06:12James Caldwell on The Hidden Culprit in Perimesencephalic SAH